Morning Market Movers: REPL, BIOA, DFNS, AXTI See Big Swings

RTTNews reports notable premarket moves ahead of Friday’s open, highlighting gainers including REPL (+131% to $12.49), AXT (+34% to $62.94), COHU (+24% to $57.70) and NWL (+19% to $6.11). Losers include BIOA (-53% to $11.64), DFNS (-49% to $43.50), GLUE (-29% to $16.00) and PN (-27% to $17.20).

Original reporting
Published Jul 31, 2026, 1:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 31, 2026, 2:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefMarket movers
Primary signal
$REPL
Bullish
low confidence
Mentioned
$REPL · $AXTI · $BIOA · $DFNS
Relevance
4/10
alphai data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$REPLBullishLow
01

Why it matters

It provides only premarket price changes for multiple tickers, with no explanation of why the moves occurred. The main trading implication is short-term volatility and momentum versus mean reversion risk into the open.

02

Market read

This is primarily a volatility watchlist for the open, not a catalyst-driven news report.

03

What to watch

Premarket percentage moves can be distorted by low volume, wide spreads, and order imbalances; traders should verify regular-session liquidity and any halt/news context before sizing.

Relevance 4/10Novelty 2/10Timing: premarket before the opening bell

Background

The article is a premarket market wrap listing stocks with large percentage gains and losses ahead of the US open.

Company-level read

Ticker impact

$REPLBullishLow confidence
Context

Premarket shows Replimune Group up 131% at $12.49, signaling a high-volatility momentum setup into the open.

Expected impact

Likely continued elevated volatility near the open, but direction is uncertain without a catalyst.

Evidence & confidence

The text reports percentage change and price only, with no news driver or follow-through details.

$AXTIBullishLow confidence
Context

AXT, Inc. is up 34% in premarket to $62.94, indicating a potential breakout or squeeze risk before regular trading.

Expected impact

Short-term upside bias possible, with high risk of pullback if liquidity thins or sellers emerge.

Evidence & confidence

Only premarket pricing is disclosed; no fundamental or event information is provided.

$BIOABearishLow confidence
Context

BioAge Labs is down 53% premarket to $11.64, implying sharp downside momentum and elevated risk of further selling.

Expected impact

Near-term downside pressure is plausible, but magnitude could be exaggerated by thin premarket liquidity.

Evidence & confidence

The article reports the decline without any accompanying news, guidance, or filing.

$DFNSBearishLow confidence
Context

T3 Defense is down 49% premarket to $43.50, a large drawdown that can trigger volatility and stop-driven flows.

Expected impact

Could remain weak at the open, but a snapback is possible if selling is overdone.

Evidence & confidence

No event driver is included; only the premarket percentage move is stated.

Market effects

No sector-level conclusions are supported because the article is a multi-name premarket movers list with no shared catalyst.

None stated; the piece is US premarket focused.

Low; it does not connect moves to macro or global events.

Counterpoint

Without a disclosed catalyst, the biggest premarket movers may be driven by liquidity and positioning, making mean reversion more likely than trend continuation.

Key entities

  • Replimune Group, Inc.

    Reported up 131% premarket to $12.49.

  • AXT, Inc.

    Reported up 34% premarket to $62.94.

  • BioAge Labs, Inc.

    Reported down 53% premarket to $11.64.

  • T3 Defense Inc.

    Reported down 49% premarket to $43.50.

Related articles

$AXTIMed

AXTI Stock Whipsaws As Leveraged ETFs And Volatility Spike

AXT Inc (AXTI) shares rose 10.82% on September 4, 2026, driven by positive sentiment and momentum trading. The semiconductor materials company reported $47.6M in quarterly revenue and $11.1M in net income, with a high P/E ratio. AXTI's stock has seen significant volatility, with intraday swings of up to 16.7%. The launch of leveraged ETFs (AXTX, AXTQ) has amplified trading activity. Management is actively engaging with investors through conferences and meetings.

$REPLHighAI 8/10

Replimune Group stock hits 52-week high at 16.2 USD

Replimune Group Inc (REPL) hit a 52-week high of $16.20, up 165.99% over the past year. Analysts have mixed views, with price targets ranging from $14 to $24. The FDA's approval of its cancer treatment, TUDRIQEV, has drawn positive attention from analysts, with upgrades and increased price targets. The company's earnings report is anticipated to impact stock movement.

$REPLLowAI 8/10

Replimune Group Lawsuit: Company Asks Court to Dismiss Securities Case Over RP1 FDA Approval Process - TipRanks.com

Replimune Group (NASDAQ: REPL) and its leaders filed a motion to dismiss a lawsuit alleging securities violations over statements about its melanoma treatment RP1's FDA approval process. The investors claim Replimune misled them about FDA feedback on the IGNYTE trial. Replimune argues it disclosed risks and that the FDA ultimately approved RP1 in August 2026.